Vcanbio Cell & Gene Engineering Balance Sheet Health
Financial Health criteria checks 6/6
Vcanbio Cell & Gene Engineering has a total shareholder equity of CN¥3.8B and total debt of CN¥35.7M, which brings its debt-to-equity ratio to 0.9%. Its total assets and total liabilities are CN¥5.4B and CN¥1.6B respectively. Vcanbio Cell & Gene Engineering's EBIT is CN¥186.1M making its interest coverage ratio -10.5. It has cash and short-term investments of CN¥1.5B.
Key information
0.9%
Debt to equity ratio
CN¥35.72m
Debt
| Interest coverage ratio | -10.5x |
| Cash | CN¥1.52b |
| Equity | CN¥3.78b |
| Total liabilities | CN¥1.59b |
| Total assets | CN¥5.37b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 600645's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 600645's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥126.4M).
Debt to Equity History and Analysis
Debt Level: 600645 has more cash than its total debt.
Reducing Debt: 600645's debt to equity ratio has reduced from 5.6% to 0.9% over the past 5 years.
Debt Coverage: 600645's debt is well covered by operating cash flow (821.4%).
Interest Coverage: 600645 earns more interest than it pays, so coverage of interest payments is not a concern.